Alvopetro Energy Ltd. (ALV.V) released a profit for its third quarter that Increased, from the same period last year
The company's earnings came in at C$8.55 million, or C$0.22 per share. This compares with C$4.61 million, or C$0.12 per share, last year.
The company's revenue for the period rose 37.0% to C$19.26 million from C$14.06 million last year.
Alvopetro Energy Ltd. earnings at a glance (GAAP) :
-Earnings: C$8.55 Mln. vs. C$4.61 Mln. last year.-EPS: C$0.22 vs. C$0.12 last year.-Revenue: C$19.26 Mln vs. C$14.06 Mln last year.
For comments and feedback contact: [email protected]
November 03, 2026 10:34 ET A key date in rare disease research. BridgeBio Pharma’s BBP-418 is under FDA Priority Review for limb-girdle muscular dystrophy type 2I/R9, a rare genetic disease with no approved treatment. The FDA decision is targeted for November 27. If approved, BBP-418 could become the first approved therapy for any form of limb-girdle muscular dystrophy.